April 2026 Research Update

This month added a few early treatment signals for idiopathic multicentric Castleman disease (iMCD), but they come from small or retrospective evidence and do not settle which approach works best. One small comparison suggested that two different immune-targeting approaches can shift many inflammation-related blood signals in similar directions, yet those blood changes did not neatly match how well people felt. A separate single-center report described long-lasting remission after stopping a specific combination regimen, which is encouraging but hard to interpret without details like how many patients were included or how remission was defined. [1] [2]

In 10 people with plasma-cell-type iMCD, filgotinib (a JAK1 inhibitor) and tocilizumab (an IL-6 receptor blocker) both led to broad lowering of multiple measured cytokines and chemokines (immune signaling proteins) over time. Only a few individual cytokines differed between the two groups, and the study also noted a mismatch between cytokine suppression and clinical improvement with filgotinib in this small sample. This supports the idea that blood markers can be informative but may not fully explain symptoms for every person or every treatment. [1]

A single-center retrospective report described iMCD patients treated with a thalidomide-cyclophosphamide-prednisone (TCP) regimen, with sustained remission reported for more than 5 years after TCP was discontinued. Because the summary does not provide the number of treated patients or details about who stopped treatment and why, it mainly adds an observation that durable remission after stopping therapy has been seen in routine care. [2]

For patients, these studies mainly add context about how researchers are trying to match treatments to the biology of iMCD and to longer-term outcomes after treatment changes. The filgotinib versus tocilizumab work is early and focused on blood immune signals, so it may matter later if it helps explain why some people improve and others do not, even when lab markers move in the expected direction. The TCP discontinuation report raises a patient-relevant question about how long remission can last after stopping therapy, but the missing details mean it is best viewed as a starting point for further study rather than a general expectation. Nothing here provides a clear, broadly applicable answer about the best treatment for an individual person. [1] [2]

Several reports this month highlighted that Castleman disease can look like other conditions, so diagnosis often depends on putting biopsy results together with the full clinical picture and, sometimes, virus testing. Across these studies, imaging and routine blood tests were not presented as decisive on their own, while tissue-based testing (looking at lymph node or mass samples) was repeatedly central. A registry study also emphasized that the "idiopathic" multicentric form (iMCD) is especially challenging because it can overlap with other syndromes and inflammatory diseases. [3] [4]

In the French national registry of 700 patients, unicentric Castleman disease (UCD) was described as usually slow-growing and often curable with surgery, while iMCD was described as heterogeneous and difficult to classify because of overlap with conditions such as POEMS, TAFRO, IgG4-related disease, and idiopathic plasmacytic lymphadenopathy. The same registry analysis noted that HHV8-positive multicentric Castleman disease, long linked to HIV, is also being recognized outside HIV. For patients, this reinforces that the label on the diagnosis (UCD vs HHV8-positive MCD vs iMCD) can matter because it reflects different patterns of illness and different diagnostic pathways. [3]

Two reports focused on distinguishing multicentric Castleman disease from IgG4-related disease using biopsy and blood protein patterns. One case of iMCD had symptoms that looked like IgG4-related disease (including pancreatitis and retroperitoneal fibrosis) but had normal IgG4 blood levels and no IgG4-positive plasma cells in the tissue sample, and the patient improved with siltuximab (an IL-6 blocker). Another case report with a systematic review suggested that a mildly elevated IgG4/IgG ratio can still fit multicentric Castleman disease and may help separate it from typical IgG4-related disease patterns. [5] [6]

A case in mixed connective tissue disease (MCTD) showed that lymph nodes can have "Castleman-like" changes without being idiopathic multicentric Castleman disease. In that patient, the lack of widespread inflammatory symptoms and the presence of high anti-U1-RNP antibodies supported a reactive process linked to the autoimmune condition rather than iMCD. For patients, it is a reminder that biopsy patterns sometimes need careful interpretation to avoid mislabeling the condition. [4]

One HIV-positive patient with HHV8-positive multicentric Castleman disease was diagnosed using a combination of histology, PET-CT imaging, and metagenomic sequencing that detected HHV8. The report described treatment with rituximab plus etoposide (R-VP16) and sustained complete remission for 36 months. Because this is one patient, it mainly adds a real-world example of how broader infectious testing can contribute to diagnosis in complex cases. [7]

For patients and caregivers, this set of studies helps clarify why getting the right diagnosis can take time and why it often requires both tissue testing and the wider health context (such as autoimmune disease, HIV status, or virus testing for HHV8). The registry data may matter now by reinforcing that Castleman disease is not one single illness, and that iMCD can be harder to pin down because of overlap with other syndromes. The IgG4-focused reports may matter later by refining how clinicians separate Castleman disease from IgG4-related disease when symptoms overlap, but they do not provide a single definitive blood test. What remains uncertain is how well any one lab marker (like an IgG4/IgG ratio) performs across diverse patients, because much of this month is based on individual cases and literature reviews. [3] [5] [6] [4] [7]

This month included several case reports showing how widely Castleman disease can present, along with a few studies that looked deeper at what might be happening in tissues and organs. Across the unicentric cases, surgery was described as the main way the diagnosis was confirmed and as the key treatment used in those reports. Across multicentric and iMCD-TAFRO case reports, the common story was complex inflammation and overlap with other conditions, with improvement described after targeted immune therapy in those individual patients. Separate organ- and tissue-level studies added clues about blood vessel lining injury in related syndromes and about stromal and immune cell interactions in a specific UCD-associated complication. [8] [9] [10] [11] [12]

Three unicentric hyaline vascular Castleman disease cases described unusual locations (posterior mediastinum, pleura, and scalp in a child) where imaging raised possibilities such as other tumor types, but the final answer came from tissue examination after surgical removal. The pleural and posterior mediastinal reports highlighted that these masses can look very vascular on imaging, yet imaging alone may not be specific enough to confirm Castleman disease. For patients, these reports reinforce that some localized forms are found incidentally or cause only local symptoms, and that the diagnosis is often made after removal and pathology testing. [8] [9] [13]

Several single-patient reports described challenging multicentric or systemic cases where the condition evolved over time. One 25-year-old developed iMCD with TAFRO syndrome after SARS-CoV-2 infection and later achieved complete remission after targeted treatment, following an initial temporary response to glucocorticoids and a relapse. Another adolescent with iMCD-TAFRO had severe inflammation together with hormone gland problems (adrenal insufficiency and autoimmune thyroiditis) and improved after glucocorticoids followed by siltuximab. [10] [14]

One report described an EBV-associated plasma cell variant Castleman disease where EBV was found in lymph node tissue even though EBV was not detected in the blood, and sustained remission was reported after third-line targeted therapy. Another HHV8-positive multicentric Castleman disease case report (with a systematic review) described diagnostic confusion on initial biopsy and later resolution after repeat biopsy and rituximab. Together, these cases underline that repeat tissue evaluation and virus testing in tissue can sometimes be important when the first explanation does not fit the full course. [15] [6]

A retrospective study comparing kidney biopsy findings across TAFRO syndrome, POEMS syndrome, and iMCD reported different patterns of injury to the tiny blood vessels in the kidney filters, with endotheliosis described in TAFRO and an MPGN-like pattern described in POEMS. The authors also noted that how soon the biopsy was done differed between groups and might affect what was seen, as well as kidney outcomes. For patients, this adds to the picture that kidney involvement in these related conditions may not look identical under the microscope, which could matter for research aimed at understanding organ damage. [11]

In a laboratory-based analysis of lymph node tissue from people with unicentric Castleman disease associated with paraneoplastic pemphigus (a serious autoimmune blistering condition), researchers reported an expansion of certain support cells and blood-vessel-related cells and changes suggesting extra basement membrane and connective tissue production. The study proposed that endothelial cells (cells lining blood vessels) may help drive collagen and laminin overproduction and communicate with B cells through specific signaling pairs. This does not predict outcomes for individual patients, but it adds a more detailed map of possible disease mechanisms in this specific UCD subgroup that could guide future research targets. [12]

For patients, these reports mainly broaden the real-world picture of what Castleman disease can look like, especially when it appears in uncommon places or overlaps with other immune or infectious conditions. The unicentric case reports and the retroperitoneal surgical series reinforce that localized disease is often managed surgically and that pathology is central to confirming the diagnosis, but case reports cannot predict any one person’s outcome. The iMCD-TAFRO and virus-associated cases show that systemic disease can have a complicated course, and that targeted immune therapy was followed by improvement in those individual patients, but the exact treatments and results may not apply widely. The tissue and kidney studies may matter later by helping explain why certain organs are affected and by pointing to potential biological pathways, yet these are primarily research tools rather than something most patients would notice in day-to-day care right now. [8] [9] [13] [10] [14] [15] [6] [11] [12] [16]